Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients

dc.contributor.buuauthorÇelebi, Solmaz
dc.contributor.buuauthorHacımustafaoğlu, Mustafa Kemal
dc.contributor.buuauthorKöksal, Nilgün
dc.contributor.buuauthorÖzkan, Hilal
dc.contributor.buuauthorÇetinkaya, Merih
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.researcheridAAG-8393-2021tr_TR
dc.contributor.scopusid7006095295tr_TR
dc.contributor.scopusid6602154166tr_TR
dc.contributor.scopusid7003323615tr_TR
dc.contributor.scopusid16679325400tr_TR
dc.contributor.scopusid23994946300tr_TR
dc.date.accessioned2021-12-20T06:39:12Z
dc.date.available2021-12-20T06:39:12Z
dc.date.issued2010-06
dc.description.abstractAim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug-resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children. Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug-resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50-75 x 103 U/kg per day was given i.v. divided into three doses. Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator-associated pneumonia (n = 14), catheter-related sepsis (n = 1) and skin and soft-tissue infection (n = 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days-15 years) and 60% were male. Mortality was 26.6%. Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. aeruginosa or A. baumannii in pediatric patients.en_US
dc.identifier.citationÇelebi, S. vd. (2010). "Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients". Pediatrics International, 52(3), 410-414.en_US
dc.identifier.endpage414tr_TR
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue3tr_TR
dc.identifier.pubmed20003141tr_TR
dc.identifier.scopus2-s2.0-77953635339tr_TR
dc.identifier.startpage410tr_TR
dc.identifier.urihttps://doi.org/10.1111/j.1442-200X.2009.03015.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1442-200X.2009.03015.x
dc.identifier.urihttp://hdl.handle.net/11452/23381
dc.identifier.volume52tr_TR
dc.identifier.wos000278803000029tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.journalPediatrics Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcinetobacter baumanniien_US
dc.subjectChildrenen_US
dc.subjectColistimethate sodiumen_US
dc.subjectNosocomial infectionen_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectVentilator-associated pneumoniaen_US
dc.subjectIntensive-care-uniten_US
dc.subjectPseudomonas-aeruginosaen_US
dc.subjectIntravenous colistinen_US
dc.subjectNosocomial infectionsen_US
dc.subjectRisk-factorsen_US
dc.subjectAcinetobacteren_US
dc.subjectPediatricsen_US
dc.subject.emtreeColistimethateen_US
dc.subject.emtreeColistinen_US
dc.subject.emtreeAcinetobacter baumanniien_US
dc.subject.emtreeAcute kidney failureen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBacterium detectionen_US
dc.subject.emtreeCatheter infectionen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeCreatinine clearanceen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHospital infectionen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeNephrotoxicityen_US
dc.subject.emtreeNeuromuscular blockingen_US
dc.subject.emtreeNewbornen_US
dc.subject.emtreePediatricsen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePseudomonas aeruginosaen_US
dc.subject.emtreeSchool childen_US
dc.subject.emtreeSepsisen_US
dc.subject.emtreeSide effecten_US
dc.subject.emtreeSkin infectionen_US
dc.subject.emtreeSoft tissue infectionen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeUniversity hospitalen_US
dc.subject.emtreeVentilator associated pneumoniaen_US
dc.subject.meshAcinetobacter baumanniien_US
dc.subject.meshAcinetobacter infectionsen_US
dc.subject.meshAdolescenten_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshColistinen_US
dc.subject.meshCross infectionen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshDrug administration scheduleen_US
dc.subject.meshDrug resistance, multiple, bacterialen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshHospitals, universityen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInfant, newbornen_US
dc.subject.meshInjections, intravenousen_US
dc.subject.meshIntensive care units, neonatalen_US
dc.subject.meshIntensive care units, pediatricen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial sensitivity testsen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshPseudomonas aeruginosaen_US
dc.subject.meshPseudomonas infectionsen_US
dc.subject.meshStatistics, nonparametricen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusColistin; Polymyxins; Ventilator Associated Pneumoniaen_US
dc.subject.wosPediatricsen_US
dc.titleColistimethate sodium therapy for multidrug-resistant isolates in pediatric patientsen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: